Celecoxib

Generic Name
Celecoxib
Brand Names
Celebrex, Elyxyb, Seglentis
Drug Type
Small Molecule
Chemical Formula
C17H14F3N3O2S
CAS Number
169590-42-5
Unique Ingredient Identifier
JCX84Q7J1L
Background

Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon...

Indication

Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
...

Associated Conditions
Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
Associated Therapies
-
Clinical Trials
Related News

Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC

Phase 2
Completed
Conditions
Non Small Cell Lung Carcinoma
First Posted Date
2005-09-16
Last Posted Date
2009-06-30
Lead Sponsor
Maastricht Radiation Oncology
Target Recruit Count
102
Registration Number
NCT00181532
Locations
🇳🇱

Maastircht Radiation Oncology, Heerlen, Limburg, Netherlands

Celebrex With Preoperative Chemoradiation - Rectal Cancer

Phase 1
Completed
Conditions
Colorectal Neoplasms
First Posted Date
2005-09-16
Last Posted Date
2010-08-13
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
39
Registration Number
NCT00188565
Locations
🇨🇦

Princess Margaret Hospital, Toronto, Ontario, Canada

Celecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip

Phase 4
Completed
Conditions
Osteoarthritis, Hip
First Posted Date
2005-09-15
Last Posted Date
2006-12-05
Lead Sponsor
Pfizer
Target Recruit Count
250
Registration Number
NCT00174317
Locations
🇬🇧

Pfizer Investigational Site, Wigan, United Kingdom

Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer

First Posted Date
2005-09-15
Last Posted Date
2010-07-02
Lead Sponsor
University of Pittsburgh
Target Recruit Count
23
Registration Number
NCT00177853
Locations
🇺🇸

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Safety of Celecoxib in Patients With Crohn's Disease

Phase 4
Terminated
Conditions
Crohn's Disease
Interventions
Drug: Celebrex
Drug: placebo
First Posted Date
2005-09-15
Last Posted Date
2016-08-29
Lead Sponsor
University of Pittsburgh
Target Recruit Count
28
Registration Number
NCT00177866

Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer

Phase 2
Completed
Conditions
Pancreatic Cancer
First Posted Date
2005-09-15
Last Posted Date
2008-05-06
Lead Sponsor
University of Michigan Rogel Cancer Center
Target Recruit Count
5
Registration Number
NCT00176813
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer

Phase 2
Completed
Conditions
Neoplasms
First Posted Date
2005-09-14
Last Posted Date
2011-07-07
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
20
Registration Number
NCT00165451
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Effect Of Celecoxib On Hip Osteoarthritis (OA) Progression

Phase 3
Terminated
Conditions
Osteoarthritis
First Posted Date
2005-09-13
Last Posted Date
2021-03-03
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
666
Registration Number
NCT00163241
Locations
🇫🇷

Pfizer Investigational Site, Vitrolles, France

Effect of Selective COX-2 Inhibition on Ulcer Healing

Phase 3
Completed
Conditions
Arthritis
Gastric Ulcer
Interventions
Drug: celecoxib
Drug: Dologesics
First Posted Date
2005-09-12
Last Posted Date
2017-04-21
Lead Sponsor
Chinese University of Hong Kong
Target Recruit Count
200
Registration Number
NCT00153673
Locations
🇨🇳

Endoscopy Center, Prince of Wales Hospital, Hong Kong, China

Celebrex - Cervix: Celecoxib in the Treatment of Patients With Locally Advanced Carcinoma of the Cervix

Phase 1
Completed
Conditions
Cervix Neoplasms
Interventions
Drug: Celecoxib
First Posted Date
2005-09-09
Last Posted Date
2016-02-09
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
31
Registration Number
NCT00152828
Locations
🇨🇦

Princess Margaret Hospital, Toronto, Ontario, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy